Fabomotizole structure
|
Common Name | Fabomotizole | ||
---|---|---|---|---|
CAS Number | 173352-21-1 | Molecular Weight | 307.411 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 504.8±60.0 °C at 760 mmHg | |
Molecular Formula | C15H21N3O2S | Melting Point | N/A | |
MSDS | N/A | Flash Point | 259.1±32.9 °C |
Use of FabomotizoleFabomotizole (CM346) is an anxiolytic drug; produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.IC50 value:Target: anxiolytic agent Afobazole's mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Afobazole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Afobazole has found little clinical use outside of Russia and has not been evaluated by the FDA. |
Name | 4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine |
---|---|
Synonym | More Synonyms |
Description | Fabomotizole (CM346) is an anxiolytic drug; produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.IC50 value:Target: anxiolytic agent Afobazole's mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Afobazole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Afobazole has found little clinical use outside of Russia and has not been evaluated by the FDA. |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 504.8±60.0 °C at 760 mmHg |
Molecular Formula | C15H21N3O2S |
Molecular Weight | 307.411 |
Flash Point | 259.1±32.9 °C |
Exact Mass | 307.135437 |
PSA | 75.68000 |
LogP | 2.68 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.635 |
Storage condition | -20℃ |
~% Fabomotizole CAS#:173352-21-1 |
Literature: Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk Patent: US6376666 B1, 2002 ; |
Afobazole |
UNII-0F8K1X115C |
1H-Benzimidazole, 6-ethoxy-2-[[2-(4-morpholinyl)ethyl]thio]- |
Fabomotizole |
Obenoxazine |
6-Ethoxy-2-{[2-(4-morpholinyl)ethyl]sulfanyl}-1H-benzimidazole |
CM 346 |